A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations
Abstract To study the effect of silymarin on the Interleukin-6 (IL-6) level, size of endometrioma lesion, pain, sexual function, and Quality of Life (QoL) in women diagnosed with endometriosis. This randomized, double-blind placebo-controlled clinical trial was performed on 70 women with endometrios...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-22073-8 |
| _version_ | 1797985983434588160 |
|---|---|
| author | Negin Mirzaei Shahideh Jahanian Sadatmahalleh Safoura Rouholamin Malihe Nasiri |
| author_facet | Negin Mirzaei Shahideh Jahanian Sadatmahalleh Safoura Rouholamin Malihe Nasiri |
| author_sort | Negin Mirzaei |
| collection | DOAJ |
| description | Abstract To study the effect of silymarin on the Interleukin-6 (IL-6) level, size of endometrioma lesion, pain, sexual function, and Quality of Life (QoL) in women diagnosed with endometriosis. This randomized, double-blind placebo-controlled clinical trial was performed on 70 women with endometriosis which was divided into two groups of intervention and control. The intervention was 140 mg silymarin (or matching placebo) administered twice daily for 12 weeks. The volume of endometrioma lesions, the level of IL-6 concentration in serum, pain, sexual function, and QoL were analyzed before and after the intervention. The means of endometrioma volume (P = 0.04), IL-6 (P = 0.002), and pain (P < 0.001) were reduced significantly in the silymarin group after intervention. However, the QoL and female sexual function did not improve substantially in the two groups (P > 0.05). Silymarin significantly reduced interleukin-6 levels, sizes of endometrioma lesions, and pain-related symptoms. The trial has been registered in the Iranian Registry of Clinical Trials (IRCT20150905023897N5) on 4th February 2020 (04/02/2020) ( https://en.irct.ir/trial/42215 ) and the date of initial participant enrollment was 2nd March 2020 (02/03/2020). |
| first_indexed | 2024-04-11T07:26:47Z |
| format | Article |
| id | doaj.art-b2403476d55248ab9825698f0e2ad203 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T07:26:47Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-b2403476d55248ab9825698f0e2ad2032022-12-22T04:37:04ZengNature PortfolioScientific Reports2045-23222022-10-0112111010.1038/s41598-022-22073-8A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestationsNegin Mirzaei0Shahideh Jahanian Sadatmahalleh1Safoura Rouholamin2Malihe Nasiri3Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares UniversityDepartment of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares UniversityDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, Isfahan University of Medical SciencesDepartment of Basic Sciences, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical SciencesAbstract To study the effect of silymarin on the Interleukin-6 (IL-6) level, size of endometrioma lesion, pain, sexual function, and Quality of Life (QoL) in women diagnosed with endometriosis. This randomized, double-blind placebo-controlled clinical trial was performed on 70 women with endometriosis which was divided into two groups of intervention and control. The intervention was 140 mg silymarin (or matching placebo) administered twice daily for 12 weeks. The volume of endometrioma lesions, the level of IL-6 concentration in serum, pain, sexual function, and QoL were analyzed before and after the intervention. The means of endometrioma volume (P = 0.04), IL-6 (P = 0.002), and pain (P < 0.001) were reduced significantly in the silymarin group after intervention. However, the QoL and female sexual function did not improve substantially in the two groups (P > 0.05). Silymarin significantly reduced interleukin-6 levels, sizes of endometrioma lesions, and pain-related symptoms. The trial has been registered in the Iranian Registry of Clinical Trials (IRCT20150905023897N5) on 4th February 2020 (04/02/2020) ( https://en.irct.ir/trial/42215 ) and the date of initial participant enrollment was 2nd March 2020 (02/03/2020).https://doi.org/10.1038/s41598-022-22073-8 |
| spellingShingle | Negin Mirzaei Shahideh Jahanian Sadatmahalleh Safoura Rouholamin Malihe Nasiri A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations Scientific Reports |
| title | A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations |
| title_full | A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations |
| title_fullStr | A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations |
| title_full_unstemmed | A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations |
| title_short | A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations |
| title_sort | randomized trial assessing the efficacy of silymarin on endometrioma related manifestations |
| url | https://doi.org/10.1038/s41598-022-22073-8 |
| work_keys_str_mv | AT neginmirzaei arandomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT shahidehjahaniansadatmahalleh arandomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT safourarouholamin arandomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT malihenasiri arandomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT neginmirzaei randomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT shahidehjahaniansadatmahalleh randomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT safourarouholamin randomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations AT malihenasiri randomizedtrialassessingtheefficacyofsilymarinonendometriomarelatedmanifestations |